2c6p: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Membrane-bound glutamate carboxypeptidase II (GCPII) is a zinc, metalloenzyme that catalyzes the hydrolysis of the neurotransmitter, N-acetyl-L-aspartyl-L-glutamate (NAAG) to N-acetyl-L-aspartate and, L-glutamate (which is itself a neurotransmitter). Potent and selective, GCPII inhibitors have been shown to decrease brain glutamate and provide, neuroprotection in preclinical models of stroke, amyotrophic lateral, sclerosis, and neuropathic pain. Here, we report crystal structures of the, extracellular part of GCPII in complex with both potent and weak, inhibitors and with glutamate, the product of the enzyme's hydrolysis, reaction, at 2.0, 2.4, and 2.2 A resolution, respectively. GCPII folds, into three domains: protease-like, apical, and C-terminal. All three, participate in substrate binding, with two of them directly involved in, C-terminal glutamate recognition. One of the carbohydrate moieties of the, enzyme is essential for homodimer formation of GCPII. The, three-dimensional structures presented here reveal an induced-fit, substrate-binding mode of this key enzyme and provide essential, information for the design of GCPII inhibitors useful in the treatment of, neuronal diseases and prostate cancer. | Membrane-bound glutamate carboxypeptidase II (GCPII) is a zinc, metalloenzyme that catalyzes the hydrolysis of the neurotransmitter, N-acetyl-L-aspartyl-L-glutamate (NAAG) to N-acetyl-L-aspartate and, L-glutamate (which is itself a neurotransmitter). Potent and selective, GCPII inhibitors have been shown to decrease brain glutamate and provide, neuroprotection in preclinical models of stroke, amyotrophic lateral, sclerosis, and neuropathic pain. Here, we report crystal structures of the, extracellular part of GCPII in complex with both potent and weak, inhibitors and with glutamate, the product of the enzyme's hydrolysis, reaction, at 2.0, 2.4, and 2.2 A resolution, respectively. GCPII folds, into three domains: protease-like, apical, and C-terminal. All three, participate in substrate binding, with two of them directly involved in, C-terminal glutamate recognition. One of the carbohydrate moieties of the, enzyme is essential for homodimer formation of GCPII. The, three-dimensional structures presented here reveal an induced-fit, substrate-binding mode of this key enzyme and provide essential, information for the design of GCPII inhibitors useful in the treatment of, neuronal diseases and prostate cancer. | ||
==Disease== | |||
Known diseases associated with this structure: Myocardial infarcation, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=602855 602855]] | |||
==About this Structure== | ==About this Structure== | ||
| Line 47: | Line 50: | ||
[[Category: zinc]] | [[Category: zinc]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 21:11:56 2007'' | ||